Description

SUSTEN VT 200 MG

Indications

SUSTEN VT 200 MG is primarily indicated for the management of various conditions related to hormonal imbalances. It is commonly prescribed for the treatment of menstrual disorders, including irregular menstrual cycles and premenstrual syndrome (PMS). Additionally, SUSTEN is utilized in hormone replacement therapy (HRT) for postmenopausal women to alleviate symptoms associated with estrogen deficiency. It may also be indicated in assisted reproductive technology (ART) protocols to support the luteal phase in women undergoing in vitro fertilization (IVF).

Mechanism of Action

SUSTEN VT 200 MG contains the active ingredient micronized progesterone, a natural progestogen. Its mechanism of action involves the regulation of the menstrual cycle and the preparation of the endometrium for potential implantation of a fertilized egg. Progesterone works by binding to progesterone receptors in target tissues, leading to changes in gene expression that promote secretory transformation of the endometrium. This action helps maintain pregnancy and supports the luteal phase, which is critical for successful implantation and fetal development.

Pharmacological Properties

The pharmacokinetics of SUSTEN VT 200 MG reveal that micronized progesterone is well absorbed when administered orally. It undergoes extensive first-pass metabolism in the liver, resulting in a bioavailability of approximately 10-15%. The peak plasma concentrations are typically reached within 1-3 hours post-administration. The drug is primarily metabolized in the liver, with metabolites excreted in the urine. The elimination half-life of micronized progesterone is about 5-20 hours, which supports its dosing regimen. SUSTEN also demonstrates a high affinity for progesterone receptors, contributing to its efficacy in managing hormonal conditions.

Contraindications

SUSTEN VT 200 MG is contraindicated in individuals with known hypersensitivity to progesterone or any of the excipients in the formulation. It should not be used in patients with a history of thromboembolic disorders, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). Additionally, SUSTEN is contraindicated in patients with undiagnosed vaginal bleeding, liver dysfunction, or active malignancies of the breast or reproductive organs. Caution is advised in patients with a history of cardiovascular disease, as progestogens may pose risks in these populations.

Side Effects

The use of SUSTEN VT 200 MG may be associated with several side effects, although not all patients will experience them. Common side effects include headache, dizziness, fatigue, and gastrointestinal disturbances such as nausea or abdominal discomfort. Some women may also experience breast tenderness or mood changes. Rare but serious side effects may include thromboembolic events, liver dysfunction, and allergic reactions. Patients should be advised to report any unusual or severe symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of SUSTEN VT 200 MG varies depending on the indication. For menstrual disorders, the typical dosage is 200 mg taken orally once daily, usually in the evening, starting from day 16 to day 25 of the menstrual cycle. For hormone replacement therapy, the dosage may range from 100 mg to 200 mg daily, depending on the estrogen regimen used. In the context of assisted reproductive technology, SUSTEN is often administered at a dosage of 200 mg two to three times daily, starting after ovulation induction and continuing until the pregnancy test. It is essential to follow the prescribing physician’s instructions regarding dosage and duration of therapy.

Interactions

SUSTEN VT 200 MG may interact with several medications, potentially altering their effects. Co-administration with other hormonal therapies may increase the risk of adverse effects and should be approached with caution. Additionally, certain anticonvulsants, antibiotics, and herbal supplements (such as St. John’s Wort) may affect the metabolism of progesterone, leading to altered plasma levels. Patients should inform their healthcare provider of all medications and supplements they are taking to assess potential interactions and adjust therapy accordingly.

Precautions

Prior to initiating treatment with SUSTEN VT 200 MG, a thorough medical history and physical examination should be conducted. Special precautions should be taken in patients with a history of depression, asthma, or diabetes mellitus, as progesterone may exacerbate these conditions. Regular monitoring is recommended for patients with cardiovascular risk factors. It is also important to consider the potential for breakthrough bleeding, especially during the initial months of therapy. Pregnant or breastfeeding women should use SUSTEN only if clearly needed and under the guidance of a healthcare provider.

Clinical Studies

Clinical studies have demonstrated the efficacy of SUSTEN VT 200 MG in various indications. In a randomized controlled trial involving women with luteal phase defects, the use of micronized progesterone significantly improved pregnancy rates compared to placebo. Another study assessing the role of progesterone in hormone replacement therapy indicated that SUSTEN effectively alleviated menopausal symptoms and improved endometrial safety. Further research is ongoing to explore additional therapeutic applications and to better understand the long-term effects of micronized progesterone in different populations.

Conclusion

SUSTEN VT 200 MG is a valuable therapeutic option for managing hormonal imbalances and supporting reproductive health. Its mechanism of action, pharmacological properties, and clinical efficacy make it a suitable choice for various indications, including menstrual disorders, hormone replacement therapy, and assisted reproductive technology. However, healthcare providers must carefully consider contraindications, potential side effects, and drug interactions when prescribing SUSTEN. Patients should be educated about the importance of adherence to the prescribed regimen and the need for regular follow-up to monitor their response to therapy.